Inspire Medical Systems
- Market cap
- 1.95B
- P/E (TTM)i
- 14.89
- P/Bi
- 2.36
- EPSi
- 4.89
- Div yieldi
- 0.00%
- 52W posi
- 26%
Anonymous reader poll. Unscientific, not investment advice.
Valuation each multiple against its own 5-year range
Vs. peers Medical Devices
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Inspire Medical Systems (INSP) | 1.95B | 14.89 | 2.36 | 0.00% |
| Abbott Laboratories (ABT) | 170.84B | 31.95 | 3.34 | 2.47% |
| Medtronic (MDT) | 109.38B | 21.06 | 2.18 | 3.33% |
| Stryker Corp (SYK) | 105.64B | 28.54 | 4.40 | 1.26% |
| Boston Scientific (BSX) | 60.26B | 16.83 | 2.42 | 0.00% |
| Edwards Lifesciences (EW) | 49.44B | 49.87 | 4.66 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 34.8% below Morningstar's fair value estimate.
Fair value
Given the significant price pressure over the last year, Inspire Medical Systems Inc might appear cheap. However, to account for the possibility that it may be a value trap, we've restricted its rating to 3 stars. The stock currently trades at a 22% discount to our quantitative fair value estimate of $90.95 per share; however, caution is warranted due to this estimate's high uncertainty rating.
The company's solid growth increases our valuation estimate. Consistent revenue and earnings growth indicates a company's potential for increased market share and profitability. For example, the firm's revenue 5-year growth of 34.1% sits in the top 10% compared with peers globally. Relatively strong trailing five-year revenue growth suggests a compelling trajectory for future sales and earnings, which contributes to our view that shares are cheap.
Conversely, the firm's liquidity is potentially concerning. Excessive liquidity may suggest inefficient capital use or limited investment opportunities. The firm's median trading volume over the past 60 days, a core component of liquidity, sits in the top 40% compared with peers globally. High trading volumes could indicate a sharp change in business model or a new growth trajectory of the business. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.
Economic moat
With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
By Quantitative Equity Report
Quote time 2026-10-08 08:21:38 · For reference only, not investment advice and not tailored to your situation.